The extent to which results of experimental toxicology studies can be used to assess risk for humans varies.
to determine which biomarkers are expressions of exposure and which are predictors of future disease. It is also unclear how lifestyle affects most biomarkers.
IndexIng Terms: species variation/toxicology/biomarkors/pharmacokinetics
Risk is the possibility of loss or injury, e.g., from losing money, having an accident, being exposed to harmful chemicals, or contracting an infectious disease. Populations living in different parts of the world and in different societies are affected by different types of risks to various degrees. In developing countries, infectious diseases, malnutrition, and infant mortality are primary concerns. In developed countries, chronic diseases, the ability to prolong life, and fear of violence have a high priority. Nonetheless, in the US, infant mortality is stifi relatively high and the prevalence of preventable communicable diseases is on the rise again. In this presentation, however, only risk related to exposure to man-made chemicals will be discussed. For acute illnesses caused by chemicals, exposure is usually high and closely related to time of onset of the ifiness. Thus, diagnosing the illness and distinguishing it from other causes of disease is relatively easy, particularly if the nature of the exposure and the identity and effects of the chemical are known (1). However, making these types of correlations for chronic diseases is much more difficult. By their nature, chronic diseases are multifactorial and may have been initiated by events that occurred many years ago, events that may be difficult to reconstruct.
For many chronic diseases, therefore, prevention is a much-emphasized, but difficult to achieve, goal. Thus, in this case, the rat would be a very poor predictor of human toxicity.
In the US, it has become common practice to select results obtained in the most sensitive species for risk assessments.
A scientifically more correct approach would be to determine why differences in response exist between species and which species represents the best surrogate to predict adverse effects in humans. Differences in response to chemicals may be the result of differences in metabolism among various species and of differences of responses at high and low doses in the same species. The rate of metabolism at high and low doses in different species and the metabolic pathways of chemicals in humans are important tools in quantitative risk assessment. Differences in concentration, binding, and distribution of the offending chemical in target cells at equilibrium may also modulate the susceptibility of different species or strains. The toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is mediated through apparently reversible binding to the aryihydrocarbon hydroxylase (Ah) receptor.' Certain mouse strains are much less susceptible to the toxic effects of TCDD than others; e.g., a dose of 25 ug/kg of body weight per week produces liver toxicity and hepatic porphyria in C57BL/6 mice but not in DBA/2 mice (11). However, differences in the Ah receptor are the primary reason for the differences in toxicity between the two strains of mice. Quantitative differences in toxicity between species administered doses of TCDD may also result from differences in tissue distribution.
At nontoxic doses, a proportionally larger amount of TCDD is stored in fatty tissue than in the liver, a target organ in many species (12). According to Carrier 
High-Dose Experimental Animal Studies
To uncover adverse effects produced by chemicals and to identify target organ toxicity, investigators usually administer high doses of chemicals to animals. Humans, however, are generally exposed to much lower doses, particularly if the exposure is environmental rather than occupational.
In the absence of human data, results from such animal studies are used to calculate an acceptable dose for humans. For noncancer end points, some laboratory animal studies may be available that provide a "no observed adverse effect level" (NOAEL). 
In the US, this result is divided by

AppropriateInterpretationof BiochemicalAlterations
Many sophisticated tests are now conducted in experimental animals and in humans to measure biochemical and physiological changes. It is frequently not clear whether these changes are early warning signs of disease in the individual with these abnormalities or whether such changes suggest that a given group of animals or humans is at a higher risk to develop a specific disease in the future. It is also not clear, after cessation of exposure, whether and to what extent such changes are repaired over time. For instance, at present we do not know whether high amounts of DNA adducts are associated with the development of cancer in specific individuals.
This would appear to depend on the type of adducts and on the cells' ability to repair the damage. The rate of cell proliferation and cell division, slow or rapid, is age-, species-, and organ-specific and would affect this process. At the moment we know little about these various mechanisms, although much speculation has been advanced.
A 
Epldemlologlcal Issues
The epidemiological issues for chemical exposures are the same as for other epidemiological studies. Two approaches to epidemiological studies are prevalent: determining whether a given exposure has resulted in illness in a population, and determining whether a given illness has been produced by exposure to a chemical. Both approaches have their problems.
Exposure
At the outset, one must determine whether exposures were sufficiently high to have resulted in adverse health effects. This frequently becomes a judgment call because, for many chemicals, adverse human health effects are unknown.
However, information from occupational exposures may be helpful. If sufficient numbers of workers have been exposed to much higher concentrations of a given chemical than the general public without experiencing ifi effects, then one may reasonably assume that the general public is not adversely affected.
Once a local source of a chemical has been identified, such as solvents in well water used as drinking water, the extent of exposure of individuals, the probable daily dose, and whether that dose makes a significant contribution to overall exposure from other sources should be determined (26 on the order of years, and past exposures can stifi be assessed at a later date. Again, such body burdens must be compared with body burdens in the general population to determine whether a given person has had a higher exposure. When making such comparisons, the arithmetic means of the "exposed" group may be higher than those of the comparison group, but the individual values may overlap. Such results should not be construed as representing differences in exposure and dose between the two groups. Instead, such observations merely suggest that the data are skewed. Frequently, log transformation of the data or calculation of geometric means will ifiustrate this point. Such differences may occur because the two populations were not matched well by age, smoking habits, liver function, or some other factor affecting the toxicokinetics of a particular chemical. In some studies, the control or comparison population was small or may not have been a truly random sample (27). As larger numbers of people are studied, the distribution range of the chemical concentrations measured usually widens and fewer outliers are observed.
Physiological factors may also affect the concentrations of chemicals in tissues and body fluids. For instance, the concentrations of lipid-soluble chemicals will be higher in serum in nonfasting specimens and in people with higher concentrations of serum lipid. They will be lower in the serum of neonates than in their mothers' serum because of the lower lipid concentrations in the blood of neonates. These factors should be considered when data are compared.
Indirect exposure measures such as induction or inhibition of enzymes, chromosome breaks, sister chromatid exchange, DNA adduct formation, lipid peroxidation, and formation of porphyrins are more difficult to evaluate. They are nonspecific and, unless careful medical and exposure histories are taken, the data cannot be interpreted.
These markers can be affected by smoking, alcohol consumption, use of specific medications, exposure to x-ray irradiation, chemotherapy, and the presence of underlying disease or congenital abnormalities.
For many of these end points, insufficient information is available from different age groups of the general population and of specific ethnic groups. It is also not clear how nutrition affects them. Finally, no prospective studies have been conducted to determine what the hea1h outcomes are in individuals with "abnormal" values for these various markers.
Disease
Very few chronic diseases have been identified as having been caused by chemicals alone; the mesotheliomas, and asbestosis and other pneumoconioses are some that have. A few studies have demonstrated that certain diseases are more prevalent after exposure to specific chemicals, e.g., chronic myelogenous leukemia after exposure to benzene and bladder cancer after exposure to f3-naphthylamine or 2-methyichioroanaline. However, these illnesses may also occur without these exposures, and in specific cases it may be difficult to determine whether a given exposure was causally associated with a specific disease. For some chronic diseases, the incidence and (or) prevalence in the general population is not very well known. Furthermore, because clinical and pathological criteria for classifying diseases and criteria for reporting diseases continue to evolve, trend analysis for some diseases is difficult.
Because of the many uncertainties and confounders affecting epidemiology studies, the scientific community is frequently divided on whether results of specific studies are overinterpreted or flawed. Under such circumstances, careful and objective analysis of all data, and perhaps additional studies, may eventually lead to more conclusive and convincing results.
